Transdermal anastrozole patch formulation and in vitro release study
DOI:
https://doi.org/10.60988/p.v37i2S.186Keywords:
anastrozole; breast cancer; transdermal patches; sustained release; chemotherapyAbstract
Anastrozole is commonly prescribed to postmenopausal women with hormone-sensitive breast cancer; however, its severe side effects – often dependent on dosage – are frequently linked to the standard oral formulation. A sustained-release transdermal delivery system may offer a means of mitigating these adverse effects. In this study, transdermal patches containing anastrozole were developed, and the influence of polymer composition on the drug’s in vitro release profile was evaluated. Polyethylene glycol 400 (PEG 400) served as a plasticizer, with varying ratios of hydrophobic to hydrophilic polymers: Eudragit L-100 and hydroxypropyl methylcellulose (HPMC), respectively. The formulations were assessed for their physicochemical properties and their in vitro drug release in phosphate-buffered solution (pH 7.4) at 32.0°C ± 1.0°C. Among these, the formulation containing a 7:3 Eudragit L-100 to HPMC ratio was selected, as its release kinetics conformed to the Higuchi model, thereby suggesting diffusion as the predominant mechanism of sustained drug release.
References
1. Hashim A.A.J., Rajab N.A. Anastrozole loaded nanostructured lipid carriers: preparation and evaluation. Iraqi J. Pharm. Sci. 30(2), 185–195, 2021. DOI: 10.31351/vol30iss2pp185-195
2. Abd Allatif K., Hasian J.A. Preparation and in vitro evaluation for different types of ondansetron hydrochloride transdermal patches. Iraqi J. Pharm. Sci. 32(1), 147–155, 2023. DOI: 10.31351/vol32iss1pp147-155
3. Al-Shaibani A.J.N., Ghareeb M.M. Formulation, in vitro and in vivo evaluation of olanzapine nanoparticles dissolving microneedles for transdermal delivery. Pharmacia 71, 1–13, 2024. DOI: 10.3897/pharmacia.71.e120974
4. Alwan L.A., Al-Akkam E.J. Formulation and evaluation of transdermal dissolved microneedles patches for meloxicam. Int. J. Drug Deliv. Technol. 11(3), 656–662, 2021. DOI: 10.25258/ijddt.11.3.2
5. Saadallah M.N., Almajidi Y.Q., Ali A. Binary ethosomal gel for enhanced transdermal delivery of tazarotene: development, refinement, in vitro evaluation, and skin penetration investigations. Al-Rafidain J. Med. Sci. 5(1S), s42–s50, 2023. DOI: 10.54133/ajms.v5i1S.288
6. Patil P., Vankani A., Sawant K. Design, optimization and characterization of atorvastatin loaded chitosan-based polyelectrolyte complex nanoparticles based transdermal patch. Int. J. Biol. Macromol. 274(1), 133219, 2024. DOI: 10.1016/j.ijbiomac.2024.133219
7. Alkhiro A.R., Ghareeb M.M. Formulation and evaluation of lornoxicam as dissolving microneedle patch. Iraqi J. Pharm. Sci. 29(1), 184–194, 2020. DOI: 10.31351/vol29iss1pp184-194
8. Altameemi K.K.A, Abd-Alhammid S.N. Anastrozole nanoparticles for transdermal delivery through microneedles: preparation and evaluation. J. Pharm. Negat. Results 13(3), 974–980, 2022. DOI: 10.47750/pnr.2022.13.03.152
9. Patel J.S., Raghavendra N.M., Sajeev Kumar B. Development and optimization of multivesicular gefitinib liposomal transdermal system employing lipoid S100 for breast cancer: pharmacokinetics, bioavailability, and skin irritation studies in Wistar rats. Futur. J. Pharm. Sci. 10, 157, 2024. DOI: 10.1186/s43094-024-00729-8
10. Hasan M.J., Rajab N.A. Nano vesicular topical drug delivery system: types, structural components, preparation techniques, and characterizations. J. Emerg. Med. Trauma Acute Care 2024(6), 16, 2024. DOI: 10.5339/jemtac.2024.absc.16
